Tag: New Jersey

Categories
Business Environment Science

Atlantic Shores Offshore Wind Project 1 signs agreement with EEW American Offshore Structures at the Port of Paulsboro Marine Terminal

ATLANTIC CITY, N.J. — (BUSINESS WIRE) — Atlantic Shores Offshore Wind Project 1, LLC (Atlantic Shores Project 1), a wholly owned subsidiary of Atlantic Shores Offshore Wind, LLC (Atlantic Shores), a 50:50 partnership between Shell New Energies US LLC and EDF-RE Offshore Development, LLC, announced it has executed a Pre-Commitment and Capacity Reservation Agreement (PCCRA) with EEW American Offshore Structures Inc. (EEW-AOS) to serve as the manufacturing company for monopiles on its 1.5 GW offshore wind project.

Located approximately 10-20 miles off the coast of Atlantic City, New Jersey, Atlantic Shores Project 1 will generate enough clean energy to power more than 700,000 homes and bring $848 million in guaranteed local economic benefits to the state. Atlantic Shores Project 1 is the largest single project awarded in New Jersey and third largest offshore wind project in the United States.

 

EEW Group is a global leader in manufacturing large-diameter steel pipes for offshore wind turbine foundations. EEW American Offshores Structures (EEW-AOS) at the Port of Paulsboro Marine Terminal in New Jersey will be the largest offshore wind manufacturing facility in the United States.

 

The PCCRA enables Atlantic Shores Project 1 to fully fabricate their monopiles in New Jersey and provides EEW-AOS the order book commitments needed to support the second phase (Phase 2) of their manufacturing facility. Atlantic Shores Project 1 will also provide future payments for start-up assistance in order to train and hire a local workforce for high-quality, in-demand jobs at the facility. EEW-AOS is working with its partners and the State of New Jersey to achieve all prerequisites to progress work on the second build-out phase at Port of Paulsboro Marine Terminal.

 

“Atlantic Shores is thrilled to partner with EEW-AOS and signal our strength as the leader of New Jersey’s clean energy economy,” said Joris Veldhoven, Chief Executive Officer of Atlantic Shores Offshore Wind. “With the recent announcements of Vestas as our turbine supplier and Ramboll as foundations designer, this agreement with EEW-AOS represents significant progress towards ‘Made in New Jersey’ monopile manufacturing and the creation of quality jobs in the Garden State. We are confident that EEW-AOS will have the site prepared to start manufacturing monopiles for Atlantic Shores Project 1 in 2024.”

 

“As a full-time resident of the Jersey Shore, I am keenly aware of our needs for both economic growth and solutions to address the significant impacts of climate change,” said Lee Laurendeau, Chief Executive Officer of EEW American Offshore Structures. “EEW-AOS is proud to partner with Atlantic Shores Project 1 on developing clean energy infrastructure that will create jobs, contribute to the local economy, and support coastal community resiliency. We are working with our partners to ensure our Phase 2 facility expansion is ready for Atlantic Shores Project 1, and to help New Jersey achieve its bold and ambitious offshore wind goals.”

 

About Atlantic Shores:

Atlantic Shores Offshore Wind, LLC (Atlantic Shores), a 50:50 partnership between Shell New Energies US and EDF Renewables. Atlantic Shores is comprised of purpose-driven professionals dedicated to delivering its 5+ gigawatt offshore wind portfolio, strategically positioned to meet the growing demands of multiple east coast markets including New York and New Jersey.

 

We invite you to learn more about Atlantic Shores Offshore Wind by visiting our website at www.atlanticsshoreswind.com and following us on our social media channels:

www.linkedin.com/company/atlantic-shores-wind
www.facebook.com/atlshoreswind
www.instagram.com/atlshoreswind
www.twitter.com/ATLShoresWind

 

About EEW Group:

For more than 85 years the EEW Group has been known as a worldwide specialist for the production of steel pipe constructions and corresponding pipe components. As a pioneer in manufacturing foundations for the offshore wind industry, the EEW Group has established itself as a leading manufacturer of foundations within the global offshore supply chain. Having built more than 2,000 monopiles and delivered structural pipe components for more than 450 jacket foundations to offshore wind projects all over the world, EEW contributes decisively on the global expansion of renewable energy. For more information, please visit https://eew-group.com/.

https://www.linkedin.com/company/eew/

Contacts

Terence Kelly

Head of External Affairs

Atlantic Shores Offshore Wind

terence.kelly@atlanticshoreswind.com
+1 (347) 834-3957

Categories
Business Healthcare

Abra Health’s Children’s Ambulatory Surgery Center obtains accreditation from AAAHC

FAIRLAWN, N.J. — (BUSINESS WIRE) — #NJ–Abra Heath’s Children’s Ambulatory Surgery Center of New Jersey is pleased to announce that it has been awarded accreditation from the Accreditation Association for Ambulatory Surgery Centers (AAAHC).


The AAAHC is a recognized leader in the accreditation of ambulatory surgery centers, and its accreditation demonstrates the Children’s Ambulatory Surgery Center’s commitment to providing high-quality, patient-centered care. The center underwent a thorough on-site review to earn its accreditation, which included evaluations of its quality of care, management, and services.

 

“We are thrilled to have received accreditation from the AAAHC,” said Mackenzie Bayer, Vice-President of Clinical Operations at the Children’s Ambulatory Surgery Center. “This achievement is a testament to the dedication and hard work of our entire team, who are committed to providing the highest level of care to our patients and their families.”

 

The Children’s Ambulatory Surgery Center is a state-of-the-art facility that offers a range of outpatient dental surgical procedures for children in a child-friendly environment. The center’s team of highly trained pediatric surgeons, anesthesiologists, nurses, and support staff are dedicated to providing exceptional care and support to children and their families.

 

The AAAHC accreditation is valid for three years, and the Children’s Ambulatory Surgery Center will continue to adhere to the highest standards of care to maintain its accreditation.

 

As an integrated health provider Abra Health also provides pediatric primary care as well as all-ages dental care in New Jersey. Providing both dental and primary care enables Abra Health patients to have easy access to a broad range of services.

 

Abra Health is slated to open new additional large-footprint multi-specialty dental and pediatric primary care offices in early and mid-2023 in northern New Jersey and eastern Pennsylvania.

 

About Abra Health

Founded in 2008 by Doctors Michael and Brooke Skolnick, a husband-and-wife dental team, Abra Health, the group formerly known as The ChildSmiles Group, is a rapidly expanding family of health practices. With multiple recent acquisitions and new locations opening regularly, the group includes several pediatric primary care and dental clinics for patients of all ages in both New Jersey and Pennsylvania. Our singular mission is to provide access to high-quality, affordable care to underserved communities. By firmly placing our patients first, we aim to deliver an exceptional experience as we improve their well-being, from teeth to toes. Our vision is to become a leading provider of integrated medical and dental care to underrepresented communities in the areas that we serve. Our ownership and leadership teams are mostly comprised of dentists. With over 700 employees, our large-footprint practices can accommodate hundreds of patients every day in an inviting, comfortable environment for both patients and staff alike.

Contacts

Media Contact Information:
Emmy Ansinelli

Abra Health

Email: eansinelli@abrahealth.com
Group website: www.abrahealthgroup.com
Children’s Surgery Website: www.abrahealthcsc.com

Categories
Healthcare Lifestyle Science

Datopotamab Deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR positive, HER2 low or negative metastatic breast cancer

  • First results for Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC in this setting reported from TROPION-PanTumor01 phase 1 trial
  • Pivotal TROPION-Breast01 phase 3 trial is ongoing, evaluating datopotamab deruxtecan in these patients in earlier lines of treatment

 

TOKYO & MUNICH & BASKING RIDGE, N.J. — (BUSINESS WIRE) — Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor (HR) positive, HER2 low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) or HER2 negative (IHC 0) unresectable or metastatic breast cancer. Safety data were consistent with previous trials of datopotamab deruxtecan. Results were presented today as a Spotlight Poster Discussion (Abstract #PD13-08) at the 2022 San Antonio Breast Cancer Symposium (#SABCS22).

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

 

Approximately 70% of breast cancer tumors are considered HR positive and HER2 low or negative.1 For patients with HR positive, HER2 low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine therapy, the current standard of care is single-agent chemotherapy.2

 

In this cohort of TROPION-PanTumor01 (n=41) where patients previously received a median of five lines of treatment for metastatic disease, datopotamab deruxtecan demonstrated an objective response rate (ORR) of 27% as assessed by blinded independent central review (BICR). All responses were partial (n=11) and 56% of patients achieved stable disease (n=23). The disease control rate (DCR) was 85% and median progression-free survival (PFS) was 8.3 months (95% confidence interval [CI]: 5.5-11.1). With median follow-up of 13.7 months (range, 9-16), the median duration of response (DoR; 95% CI: 4.4-NE) and the median overall survival (OS) had not been reached with 59% of patients alive for more than one year.

 

“Patients with HR positive, HER2 low or negative metastatic breast cancer who are not eligible for endocrine therapy or have exhausted treatment options have a poor prognosis,” said presenting author Funda Meric-Bernstam, MD, Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. “These preliminary results with datopotamab deruxtecan in patients with heavily pretreated HR positive, HER2 low or negative metastatic breast cancer are encouraging and warrant further evaluation in this setting.”

 

The safety profile of datopotamab deruxtecan was consistent with previous data with no new safety signals identified. The most common grade 3 or higher treatment-emergent adverse events (TEAEs) were decreased lymphocyte count (15%), stomatitis (10%), anemia (7%), dyspnea (2%) and fatigue (2%). Serious TEAEs were observed in six (15%) patients, including one death due to dyspnea that was not considered treatment-related. Treatment discontinuations due to an adverse event occurred in five (12%) patients. No cases of grade 3 or higher diarrhea or febrile neutropenia were observed. One case of grade 3 interstitial lung disease was adjudicated as treatment-related.

 

“These results add to the growing body of data demonstrating the potential of datopotamab deruxtecan to treat certain types of metastatic breast cancer,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “We look forward to the continued evaluation of our TROP2 directed antibody drug conjugate, including comparisons to standard therapy in earlier lines of treatment for HR positive, HER2 low or negative metastatic breast cancer through our ongoing TROPION-Breast01 phase 3 trial.”

 

“Many of these patients with metastatic breast cancer in TROPION-PanTumor01 had exhausted most of their available treatment options, having received a striking median of five prior regimens, including a CDK4/6 inhibitor for nearly all patients,” said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. “These promising results with datopotamab deruxtecan in such a heavily pretreated patient population support our strong belief that this TROP2 directed antibody drug conjugate has the potential to improve outcomes for patients with HR positive, HER2 low or negative breast cancer in this, and possibly earlier settings.”

 

Patients in this cohort were heavily pretreated, receiving a median of five prior lines of treatment in the metastatic setting (range, 3-10). Prior treatments included CDK4/6 inhibitors (95%), capecitabine (83%), taxanes (59%), anthracyclines (54%), neoadjuvant chemotherapy (37%), mTOR inhibitors (29%) and PI3KCA inhibitors (20%). As of data cut-off on July 22, 2022, five patients remained on study treatment.

 

Summary of Results

Efficacy Measure

Datopotamab Deruxtecan (6 mg/kg) n=41

Confirmed ORR, %i,ii

27% (n=11)

PR, %

27% (n=11)

SD, %

56% (n=23)

Non-CR/non-PD, %

2% (n=1)

PD, %

12% (n=5)

NE, %

2% (n=1)

DCR, %i,iii

85% (n=35)

Median DoR (months) (95% CI)i

NE (4.4-NE)

Median PFS (months) (95% CI)i

8.3 months (5.5-11.1)

Median OS (months)

Not reached

CI, confidence interval; CR, clinical response; DCR, disease control rate; DoR, duration of response; NE, not evaluable; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease

i As assessed by BICR

ii ORR is (CR + PR)

iii DCR is (CR + PR + SD + non-CR/non-PD)

 

Daiichi Sankyo and AstraZeneca have a broad clinical development program for datopotamab deruxtecan in breast cancer, including the ongoing pivotal TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan in patients with HR positive, HER2 low or negative, inoperable or metastatic breast cancer previously treated with chemotherapy.

 

About TROPION-PanTumor01

TROPION-PanTumor01 is a first-in-human, open-label, two-part, multicenter phase 1 trial evaluating the safety and preliminary efficacy of datopotamab deruxtecan in patients with advanced solid tumors that have relapsed or are refractory to standard treatment or for which no standard treatment is available. The dose escalation portion of the trial enrolled patients with non-small cell lung cancer (NSCLC) to assess the safety and efficacy of datopotamab deruxtecan to determine the recommended dose for expansion (6 mg/kg). The dose expansion part of TROPION-PanTumor01 is enrolling several different cohorts including patients with NSCLC, triple negative breast cancer (TNBC), HR positive, HER2 low or negative breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, castration-resistant prostate and esophageal cancer.

 

Safety endpoints include dose-limiting toxicities and serious adverse events. Efficacy endpoints include ORR, DoR, time to response, PFS and OS. Pharmacokinetic, biomarker and immunogenicity endpoints also are being evaluated.

 

About HR Positive, HER2 Low or Negative Breast Cancer

Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide.3 More than two million breast cancer cases were diagnosed in 2020 with nearly 685,000 deaths globally.3

 

Breast cancer is considered HR positive, HER2 low or negative when the tumors test positive for estrogen and/or progesterone hormone receptors and low for HER2 (measured as a HER2 score of IHC 1+ or IHC 2+/ISH-) or negative for HER2 (measured as IHC 0).1,4 This subtype accounts for approximately 70% of diagnosed breast cancer cases and is associated with lower survival rates with 30% of patients anticipated to live beyond five years after diagnosis.1 Current standard of care treatment for patients with HR positive, HER2 low or negative metastatic breast cancer that progress on hormone therapy-based regimens is sequential single-agent chemotherapy, which is associated with a low median PFS of less than 10 months and OS of less than two years, underscoring the need for additional treatment options.2,5,6,7

 

TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is broadly expressed in several types of solid tumors, including HR positive, HER2 low or negative breast cancer.8,9 TROP2 expression is an unfavorable prognostic factor for overall survival in all types of breast cancer.8

 

About Datopotamab Deruxtecan (Dato-DXd)

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.

 

A comprehensive development program called TROPION is underway globally with more than 10 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple TROP2 targetable tumors, including NSCLC, TNBC and HR positive, HER2 low or negative breast cancer. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

 

About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize datopotamab deruxtecan in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for the manufacturing and supply of datopotamab deruxtecan.

 

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.

 

References:

1 National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed December 2022.

2 NCCN Treatment Guidelines for Breast Cancer. Version 4.2022.

3 Sung H, et al. CA Cancer J Clin. 2021;10.3322/caac.21660.

4 Iqbal N, et al. Mol Biol Int. 2014;852748.

5 Cortes J, et al. Lancet. 2011;377:914-923.

6 Yuan P, et al. Eur J Cancer. 2019;112:57-65.

7 Jerusalem G, et al. JAMA Oncol. 2018;4(10):1367–1374.

8Goldenberg D, et al. Oncotarget. 2018;9(48): 28989-29006.

9 Zaman S, et al. Onco Targets Ther. 2019;12:1781–1790.

Contacts

Media Contacts:

Global/US:
Rose Talarico

Daiichi Sankyo, Inc.

rtalarico@dsi.com
+1 973 775 0838 (mobile)

EU:
Simone Jendsch-Dowé

Daiichi Sankyo Europe GmbH

simone.dowe@daiichi-sankyo.eu
+49 (89) 78080 (office)

Japan:
Koji Ogiwara

Daiichi Sankyo Co., Ltd.

ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations:
DaiichiSankyoIR@daiichisankyo.co.jp

Categories
Business Lifestyle Local News Science

Universal Display Corporation named to Newsweek’s America’s Most Responsible Companies for third consecutive year

EWING, N.J. — (BUSINESS WIRE) — $OLED #OLED—Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today that the Company was named to Newsweek’s list of America’s Most Responsible Companies 2023.

 

Universal Display ranked #215 on the 2023 list, which recognizes the top 500 most responsible companies in the United States across fourteen different industries. This is UDC’s third consecutive year on the list.

“We are pleased to be recognized for the third year among America’s most responsible companies,” said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation.

 

“For more than two-and-a-half decades, we have focused on cultivating and fostering a global culture that promotes inclusion, inventiveness, integrity and imagination. We also endeavor to contribute to creating a sustainable and low-carbon future through our energy-efficient portfolio of OLED solutions, including our award-winning phosphorescent OLED technology and UniversalPHOLED materials that are proven, and integral to enabling high performance, low-power consumption and energy-efficiency in OLED displays and lighting.”

 

Newsweek partnered with Statista to recognize the top 500 most responsible companies in the United States. America’s Most Responsible Companies were selected based on publicly available key performance indicators derived from CSR Reports, Sustainability Reports, and Corporate Citizenship Reports as well as an independent survey of more than 13,000 U.S. residents. The ranking focuses on a holistic view on corporate responsibility that considers the three pillars of ESG: Environment, Social and Corporate Governance. For more details on the methodology, please visit https://cdn.statcdn.com/rankings/Methodology_Americas_Most_Responsible_Companies_2023.pdf.

 

For more information about Universal Display Corporation’s corporate social responsibility commitment, please visit https://ir.oled.com/shareholders/Corporate-Responsibility/default.aspx.

 

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 5,500 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

 

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.

 

All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2021. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

 

Follow Universal Display Corporation

Twitter
Facebook
YouTube

(OLED-C)

Contacts

Universal Display Contact:
Darice Liu

investor@oled.com
media@oled.com
+1 609-964-5123

Categories
Business Healthcare Lifestyle

PAX debuts new PAX Era device and High Purity THC

Offers consumers the perfect blend of potency and flavor, at an accessible price

 

SAN FRANCISCO — (BUSINESS WIRE) — #PAXlife—PAX, a leading global cannabis brand, today announced the launch of its latest cannabis experience—the all new PAX Era vaporizer device and High Purity THC pod, the fourth cannabis product to come to market from PAX this year. Designed to work perfectly together, the new Era lineup offers consumers more vapor and a new anti-clog feature, while PAX High Purity THC pods offer a high potency experience at the brand’s most accessible price point to date.


“We’re excited to continue to expand our cannabis offerings to better meet the needs and lifestyles of our customers, especially those who want the clean, high quality products PAX has staked its reputation on,” said Steven Jung, Chief Operating Officer at PAX. “In this case, we’re delivering a high performing closed-loop system, paired with our High Potency THC, to provide the perfect blend of unique flavors and potency at an accessible price.”

 

PAX Era

Building on more than a decade of innovation and industry leading standards, the newest device from PAX’s rechargeable closed-loop battery and pod system, PAX Era, has been re-engineered to heat faster and produce more vapor, delivering hits up to 50% bigger than previous generations. An intuitive new anti-clog feature works automatically to prevent clogs. PAX’s patented temperature control heats, and never burns, for consistent flavors and aromas from start-to-finish for every pod. All devices are backed by a 1-year limited warranty.

 

The lineup offers three vibrant new colorways, Ultra Pink, Ultra Blue, and Ultra Green, in addition to a classic Black, with a MSRP starting at $35. PAX Era devices are available to consumers on pax.com or through licensed retailers in 20 states, including Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Missouri, Nevada, New Jersey, New Mexico, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah and Washington.

 

PAX High Purity THC

PAX’s High Purity THC pods are California cannabis oil, sourced for purity and potency, enhanced with a blend of terpenes to bring out unique flavor and taste profiles. Available in six flavor-forward cultivars, including Limoncello Haze (Sativa), Strawberry Créme (Sativa), Berry Gelato (Hybrid), Forbidden Fruit (Hybrid), London Pound Cake (Indica), and GMO Cookies (Indica) each with 85%+ THC. All PAX pods are made with food grade materials and tested to medical standards, certified free from residual solvents, cutting agents, harmful heavy metals, toxins and contaminants. Available across California, PAX’s High Purity THC starts at $30 for 1G, providing the lowest-cost introduction to the PAX platform.

 

PAX is a leading global cannabis brand on a mission to enhance people’s lives through exceptional cannabis experiences. PAX’s curated set of pure, full-flavor products and award-winning devices make enjoying cannabis clean, simple and safe. For more than a decade, PAX has created high performance devices that deliver enduring quality through innovations in design and technology, and remain trusted by millions of consumers nationwide. The PAX brand believes in creating sustainable well-being and building opportunity through cannabis. pax.com

 

NOT FOR SALE TO MINORS. Final Bell Lic. No. C12-0000266-LIC. © 2022 PAX Labs, Inc. All Rights Reserved. PAX, X, and ERA are all trademarks of PAX Labs, Inc. Patents and Trademarks: pax.com/IP.

Contacts

press@pax.com

Categories
Business Healthcare Science

Tevogen Bio to study its investigational COVID-19 T cell therapy in immunocompromised patients who are unable to benefit from currently available prevention or treatment options

  • Tevogen’s investigational precision T cell product, TVGN-489, is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the entire SARS-CoV-2 genome.
  • The immunocompromised COVID-19 patients who are unable to take or unlikely to benefit from currently available prevention or treatment strategies are amongst the most vulnerable.
  • Given that no dose limiting toxicities or treatment-related adverse events were observed in the TVGN 489 POC trial, half of whom were immunosuppressed patients, Tevogen now plans to move forward with a clinical trial to study the efficacy of its product in this patient population.
  • Tevogen’s research pipeline includes cell therapies for treatment of COVID-19, long COVID, viral-induced cancers and neurologic diseases, including multiple sclerosis; and several non-virally induced cancers.

 

WARREN, N.J. — (BUSINESS WIRE) — #COVID19—Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in oncology, neurology, and virology today announced its intention to study the potential therapeutic use of its investigational COVID-19 T cell therapy, TVGN-489, in immunocompromised patients.

“I’m greatly encouraged by the POC trial experience of TVGN 489 and highly optimistic that our investigational COVID-19 therapy will eventually offer hope to a substantial segment of high-risk COVID patients.” said Dr. Dolores Grosso, Tevogen’s Clinical Development Lead.

 

There exists a significant unmet need for the treatment of COVID-19 in immunocompromised patients. Currently, there are very few treatment options that have not been impacted by variants or are suitable for this patient population due to possible medication interactions. A comprehensive review, completed by the company’s Research and Development team, led by Dr. Neal Flomenberg, Tevogen’s Chief Scientific Officer, found that TVGN-489 is expected to retain activity against recent variants, including XBB and BQ and its subtypes, which appear to have the ability to evade some existing prophylactic options and immunity. “The lack of treatment options places immunocompromised patients at higher risk of developing poor outcomes if infected with SARS-CoV-2,” said Dr. Flomenberg.

 

“It is everyone’s responsibly to step up during a moment of crisis, and for those of us in the medical innovation industry, it is our moral obligation. And we will do everything in our power to save as many lives as we can,” said Tevogen CEO Ryan Saadi, M.D., M.P.H.

 

About Tevogen’s Next Generation Precision T Cell Platform

Tevogen’s next generation precision T cell platform is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming the mutational capacity of cancer cells and viruses which can otherwise allow for escape from immunologic targeting.

 

Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

 

Tevogen announced the completion of patient enrollment in the Proof-of-Concept clinical trial of its lead product, TVGN-489, for ambulatory, acute-risk COVID-19 patients, with no dose-limiting toxicities or significant treatment-related adverse events observed for any patient at any dose level.

 

TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the entire SARS-CoV-2 genome.

 

About Tevogen Bio

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

 

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.

Contacts

Tevogen Communications

T: 1 877 TEVOGEN, Ext 714

Communications@Tevogen.com

Categories
Business Environment Lifestyle

New Jersey Resources named one of America’s Most Responsible Companies by Newsweek

WALL, N.J. — (BUSINESS WIRE) — For the fourth consecutive year, New Jersey Resources (NYSE: NJR) was named one of America’s Most Responsible Companies by Newsweek in recognition of its excellence and accomplishments in corporate social responsibility.

NJR was selected from a pool of 2,000 companies across 14 industries that were evaluated and ranked based on a detailed analysis of key performance indicators in three areas of corporate social responsibility: environmental, social and corporate governance. The final list recognizes the top most responsible companies in the United States and reinforces NJR’s commitment to corporate sustainability and reputation for service excellence.

 

“New Jersey Resources is committed to advancing a clean energy future by embracing sustainable business practices that meet the energy needs of our customers, benefit the environment and strengthen the communities we serve,” said Steve Westhoven, President and CEO of New Jersey Resources. “It is an honor to be recognized as one of the most responsible companies in the country. This recognition reflects our belief that sustainability and corporate citizenship are good for business, good for our customers and good for the future.”

 

Environmental stewardship and sustainability are priorities for NJR, and the company is committed to achieving net-zero emissions from its New Jersey operations by 2050. Its principal subsidiary, New Jersey Natural Gas, which keeps homes and businesses warm for nearly 570,000 customers throughout New Jersey, is leading the way to help reduce emissions – building the first green hydrogen project on the East Coast; modernizing its infrastructure to build the most environmentally sound delivery systems in the state, as measured by leaks per mile; and helping customers reduce energy consumption through its energy-efficiency initiatives. In addition, NJR’s renewable energy subsidiary Clean Energy Ventures is one of the largest owner/operators of solar projects in the state with over $1 billion invested in building clean, emissions-free power for homes and businesses.

 

To learn more about NJR’s leadership and commitment to sustainability, please visit www.njrsustainability.com.

 

America’s Most Responsible Companies 2023 is a project of Newsweek in partnership with Statista. For more information on the rankings and methodology for selection, please visit newsweek.com/americas-most-responsible-companies-2023.

 

About New Jersey Resources

New Jersey Resources (NYSE: NJR) is a Fortune 1000 company that, through its subsidiaries, provides safe and reliable natural gas and clean energy services, including transportation, distribution, asset management and home services. NJR is composed of five primary businesses:

 

  • New Jersey Natural Gas, NJR’s principal subsidiary, operates and maintains over 7,700 miles of natural gas transportation and distribution infrastructure to serve over 569,000 customers in New Jersey’s Monmouth, Ocean and parts of Morris, Middlesex and Burlington counties.
  • NJR Clean Energy Ventures invests in, owns and operates solar projects with a total capacity of more than 386 megawatts, providing residential and commercial customers with low-carbon solutions.
  • NJR Energy Services manages a diversified portfolio of natural gas transportation and storage assets and provides physical natural gas services and customized energy solutions to its customers across North America.
  • Storage & Transportation serves customers from local distributors and producers to electric generators and wholesale marketers through its ownership of Leaf River and the Adelphia Gateway Pipeline Project, as well as our 50% equity ownership in the Steckman Ridge natural gas storage facility.
  • NJR Home Services provides service contracts as well as heating, central air conditioning, water heaters, standby generators, solar and other indoor and outdoor comfort products to residential homes throughout New Jersey.

 

NJR and its nearly 1,300 employees are committed to helping customers save energy and money by promoting conservation and encouraging efficiency through Conserve to Preserve® and initiatives such as The SAVEGREEN Project® and The Sunlight Advantage®.

 

For more information about NJR: www.njresources.com.

 

Follow us on Twitter @NJNaturalGas.
“Like” us on facebook.com/NewJerseyNaturalGas.

Contacts

Media:
Mike Kinney

732-938-1031

mkinney@njresources.com

Investor:
Adam Prior

732-938-1145

aprior@njresources.com

Categories
Culture Lifestyle

Seniors get ultimate gift at surprise holiday party with over 25,000 lights, musicians, and hundreds of visitors

Klick Health produces ‘Light The Way’ holiday video with long-term care home to help minimize loneliness among seniors during the holidays

 

TORONTO & NEW YORK — (BUSINESS WIRE) — The holiday season can be a lonely time for many seniors–increasingly so since the start of the pandemic–so Klick Health today released its ‘Light The Way’ holiday video to encourage people to “be the light in someone’s day.” The sentimental three-minute holiday production was created in partnership with the Tony Stacey Centre for Veterans Care (TSCVC) and shines a spotlight on the power of community and connection.


Set to original, new music by singer/songwriter Taylor Ashton, ‘Light The Way’ provides a heartwarming glimpse inside the non-profit long-term care home as Klicksters work outside to surprise residents with a larger-than-life holiday celebration. In the video, hundreds of family, friends, Klicksters, and community members turn up in droves for the event, featuring over 25,000 lights, a giant Santa throne and other festive decor, live entertainment, and hot cocoa.

 

“We are grateful to everyone at the Tony Stacey Centre for collaborating with us to bring to life such an important story,” said Chief Creative Officer Rich Levy. “Making this video has been a labor of love that has brought together the expertise of so many Klick crafts–from creative and production, to medical, events & experience, and more–all to bring joy and togetherness to an often overlooked community.”

 

According to the TSCVC, 75 percent of its residents don’t receive any visitors during the holiday season. Recently published research in the Journal of the American Heart Association found that social isolation and loneliness increase the risk of heart attack, stroke, or death by 30 percent. For many seniors, the ongoing COVID-19 pandemic has only made loneliness worse, and the holidays can be an especially difficult time.

 

Raising funds and awareness for long-term care homes

Klick’s Chief People Officer Glenn Zujew said, “We’ve been creating annual holiday videos to help spread festive cheer and give back to communities for over a decade, but this one is extra special. There’s a beautiful and tender emotionality to ‘Light The Way’ that we hope resonates around the world, and reminds everyone that human connection is the ultimate holiday gift.”

 

‘Light The Way’ also supports TSCVC’s ongoing fundraising efforts, with Klick donating $1 for each of the video’s first 10,000 YouTube views to the Toronto long-term care home, which has launched a fundraising campaign to redevelop its aging building. The company is also supporting a New Jersey-based long-term care home, sending homemade holiday cards to its residents and adding the care residence to its internal Klick it Forward charitable giving platform for the month of December, so Klicksters can direct the donation dollars they receive there.

 

In past years, Klick’s holiday videos have inspired millions of people with themes of kindness, empathy, and creativity. Last year, the company gave hundreds of its team members each a $100 bill with the simple directive to use it to ‘Spread Joy.’ Its popular 2020 ‘When Nobody’s Watching’ animated video received almost five million YouTube views, while its 2019 ‘Kindness is Contagious’ production received six million views and won a Webby Award. In 2019, the CW Network featured Klick’s ‘Epic Office Holiday Remix with Andrew Huang’ on its ‘Greatest Holiday Commercials Countdown’ show.

 

Klick’s ‘Light The Way’ holiday video can be viewed, liked, and shared on YouTube at https://www.youtube.com/watch?v=hjoytc_KoMQ.

 

About Klick Health

Klick Health is the world’s largest independent commercialization partner for life sciences. For over 25 years, Klick has been laser-focused on developing, launching, and supporting life sciences brands to maximize their full market potential as a core commercialization partner. Klick recently ranked #1 on Medical Marketing + Media (MM+M) magazine’s Agency 100 list for the fifth straight year and was named an MM+M Large Agency of the Year for both 2020 and 2021, marking 10 Agency of the Year industry awards in 11 years. Follow Klick Health on LinkedIn and for more information on joining Klick, go to careers.klick.com.

 

About Klick Group

The Klick Group of companies–Klick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs–is an ecosystem of brilliant talent collectively working to maximize their people’s and clients’ full potential. Established in 1997, Klick has teams across North America, with offices in New York, Philadelphia, and Toronto, and is opening global offices in Basel, Buenos Aires, London, Munich, Paris, Singapore, São Paulo, and Tokyo. Klick has consistently been named a Best Managed Company and Great Place to Work. In 2021, the company was recognized with 15 Best Workplace awards, including Best Workplaces for Women, Best Workplaces for Inclusion, Best Workplaces for Giving Back, Fast Company’s Best Workplaces for Innovators, and FORTUNE’s Best Workplaces for Millennials.

Contacts

For media inquiries:
Marisa McWilliams, Senior Manager, Communications, Klick Health

Email: pr@klick.com
Phone: 862-335-8165

Amanda Ferguson, Manager, Communications, Klick Health

Email: pr@klick.com
Phone: 416-214-4977

Categories
Business

AM Best comments on Credit Ratings of Fidelis Insurance Holdings Limited and its subsidiaries

OLDWICK, N.J. — (BUSINESS WIRE) — #insurance–Fidelis has received regulatory approvals for the separation of its current configuration into a balance sheet company, which will continue to hold reserves, record the premiums issued, pay claims, manage investments, and utilize a managing general underwriter (MGU), which will underwrite business on behalf of the balance sheet entity. The transaction is expected to close in early January 2023 and is evolving in line with AM Best’s expectations.

Fidelis’ Credit Ratings (ratings) will remain under review with negative implications following its announcement that certain regulatory approvals have been secured. Specifically, these ratings include the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Fidelis Insurance Bermuda Limited (Fidelis) (Bermuda), Fidelis Underwriting Limited (United Kingdom) and Fidelis Insurance Ireland Designated Activity Company (Ireland), as well as the Long-Term ICR of “bbb” (Good) of Fidelis Insurance Holdings Limited (Bermuda), the ultimate holding company, including the Long-Term Issue Credit Rating of “bb+” (Fair) of Fidelis Insurance Holdings Limited’s $304 million ($58 million currently outstanding) 9% preference shares due 2050. The under review with negative implications status will be resolved once the transaction is completed.

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2022 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Guilherme Monteiro Simoes, CFA
Senior Financial Analyst
+1 908 439 2200, ext. 5301
guy.simoes@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Steven Chirico, CPA
Director
+1 908 439 2200, ext. 5087
steven.chirico@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 439 2200, ext. 5098
al.slavin@ambest.com

Categories
Healthcare Lifestyle

Pinnacle Treatment Centers opens Lacey Treatment Services in New Jersey to provide opioid addiction treatment

LANOKA HARBOR, N.J. — (BUSINESS WIRE) — Pinnacle Treatment Centers, a leader in providing accessible, affordable care for people seeking treatment for opioid use disorder, has opened Lacey Treatment Services in New Jersey. Located at 411 Route 9, Suite 1, the community-based program serves as Pinnacle’s 11th outpatient location in the Garden State.


According to the office of the Chief State Medical Examiner, Ocean County remains as one of the top three counties in New Jersey for suspected overdose deaths, behind Camden and Essex counties.

 

Medicaid-friendly, Lacey Treatment Services will offer medication-assisted treatment (MAT) for adult men and women, including FDA-approved medicines such as methadone and buprenorphine, which curb withdrawal symptoms from heroin and opioid addiction; prevent relapse; and help ease the physical discomfort that accompanies opioid recovery. Individual counseling, group counseling and peer support services are provided as part of a holistic approach to patient care.

 

MAT is proven to be clinically effective and significantly reduces the need for inpatient withdrawal management services, which means lower costs to payors and less disruption in the lives of patients seeking recovery.

 

Lacey Treatment Services’ treatment team is comprised of seasoned doctors, registered nurses, and credentialed clinical therapists who have all worked in medication-assisted treatment and bring a wealth of knowledge and experience to the team. “The team we have assembled to treat this community brings a wealth of knowledge and long-time experience working in MAT. We are incredibly proud of this team and their drive to provide much needed services locally,” said Regional Vice President, Chris White. Lacey Treatment Services Assistant Executive Director, Dana Mills is motivated to get patients on track “We are here to be helpful and caring to the patients that need our services. In addition to medication and counseling, we will be able to provide peer support and case management services to eligible patients. This will allow us to connect these patients to resources who can assist with areas they may be struggling with, such as housing, health or dental services, employment, education, and other social services. Our goal is to give our patients the best chance possible at restoring their lives.”

 

Lacey Treatment Services accepts Medicaid, commercial insurance, and offers reasonable self-pay rates. The center is open Mondays through Fridays, 5:30 a.m.- 12 p.m., and on Saturdays, 5:30 a.m.- 12 p.m. Individuals can call 609-357-4428 for a free, confidential assessment.

 

Pinnacle’s 11 addiction treatment centers in New Jersey include:

  1. Delaware Valley Medical (Pennsauken)
  2. Hamilton Treatment Services
  3. Middletown Medical and Suboxone Services of Monmouth County
  4. Ocean Medical Services (Toms River)
  5. Ocean Monmouth Care (Brick) and Suboxone Services of Brick
  6. Pennsville Treatment Services
  7. Stateline Medical (Phillipsburg) and Suboxone Services of Phillipsburg
  8. Suboxone Services of Manahawkin
  9. Suboxone Services of Toms River
  10. Vineland Treatment Services
  11. Lacey Treatment Services

 

About Pinnacle Treatment Centers

Headquartered in Mount Laurel, New Jersey, Pinnacle Treatment Centers is a recognized leader in comprehensive drug and alcohol addiction treatment serving more than 35,000 patients daily in California, Georgia, Indiana, Kentucky, North Carolina, New Jersey, Ohio, Pennsylvania, and Virginia. With more than 135 community-based locations, Pinnacle provides a full continuum of quality care including medically-monitored detoxification/withdrawal management, Acute psychiatric stabilization for individuals with co-occurring substance use and mental health (dual diagnosis) treatment., residential treatment, partial hospitalization, recovery residences, intensive and general outpatient programming, and outpatient medication-assisted treatment (MAT) for opioid use disorder. For more information, visit pinnacletreatment.com.

Contacts

Media:
Jules Czukor

Director of Marketing

Pinnacle Treatment Centers

215-630-5006 | jules.czukor@pinnacletreatment.com